Redundant Human Omentum Fat: A Leap Towards Regenerative Medicine

  • Somasundaram Indumathi
  • Radhakrishnan Harikrishnan
  • Marappagounder Dhanasekaran


Mesenchymal stem cells possess a ground-breaking potential and appear to offer a wonderful opportunity, indeed a responsibility to understand important aspects of human biology involving tissue repair and regeneration. The ubiquitous existences of multipotent mesenchymal stem cells (MSCs) annex to be a regenerative tool rendering the replacement of worn-out cells. Researchers have averted their attention towards identification of various sources of adult mesenchymal stem cells from our own body tissues and fluids. Despite the existence of several advantages and potentials of MSCs from several sources being investigated, bringing stem cells adaptable for regenerative medicine applications in adequate quantities at the right time is a challenge. This is with regard to the inevitable fact that the frequencies of mesenchymal stem cells and their proliferative capacities and differentiation potentials as well as phenotypical and immunomodulatory properties have been shown to vary among sources. Furthermore, cell-based therapies rely to a larger degree on the preparation of an effective dose of ex vivo expanded cells, capable of self-renewal and differentiation. The identification of physiologically relevant and ideal source of stem cells that might be more useful in clinical setting needs to be investigated to ascertain an assured quality in cellular therapy. Additionally, changing the perception, about the successful treatment of stem cells for various diseases, in the light of recent findings becomes mandatory to cure these diseases and further to broaden the potential applications of stem cells. Adult stem cell therapies are routinely used to treat diseases using umbilical cord blood stem cell transplants and peripheral blood stem cell and bone marrow stem cell transplants which are probably the most well-known therapy.


Stem Cell Mesenchymal Stem Cell Subcutaneous Adipose Tissue Peripheral Blood Stem Cell Stromal Vascular Fraction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic transplants of bone marrow: analysis of precursor cells for osteogenic and haematopoietic tissues. Transplantation. 1968;6:230–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Salingcarnboriboon R, Yoshitake H, Tsuji K, et al. Establishment of tendon-derived cell lines exhibiting pluripotent mesenchymal stem cell-like property. Exp Cell Res. 2003;287(2):289–300.PubMedCrossRefGoogle Scholar
  4. 4.
    Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet. 2004;2004:149–55.CrossRefGoogle Scholar
  5. 5.
    De Bari C, Dell’Accio F, Tylzanowski P, et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44:1928–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Sabatini F, Petecchia L, Tavian M, et al. Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Invest. 2005;85:962–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Campagnoli C, Irene AG R, Kumar S, et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98:2396–402.PubMedCrossRefGoogle Scholar
  8. 8.
    Musina RA, Belyavski AV, Tarusova OV, et al. Endometrial mesenchymal stem cells isolated from the menstrual blood. Bull Exp Biol Med. 2008;145:539–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Jones EA, English A, Henshaw K, et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum. 2004;50:817–27.PubMedCrossRefGoogle Scholar
  10. 10.
    In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003;102:1548–9.CrossRefGoogle Scholar
  11. 11.
    Gargett CE, Schwab KE, Zillwood RM, et al. Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod. 2009;80:1136–45.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1997;20:369–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation. Circulation. 2006;114:I-101–7.CrossRefGoogle Scholar
  15. 15.
    Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuethe F, Richartz BM, Kasper C, et al. Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans. Int J Cardiol. 2005;100:485–91.PubMedCrossRefGoogle Scholar
  17. 17.
    Kumar AA, Kumar SR, Narayanan R, et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009;7:241–8.PubMedGoogle Scholar
  18. 18.
    Rebelatto CK, Aguiar AM, Moretio, et al. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med. 2008;233:901–13.CrossRefGoogle Scholar
  19. 19.
    Locke M, Windsor J, Dunbar PR. Human adipose-derived stem cells: isolation, characterization and applications in surgery. ANZ J Surg. 2009;79:235–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Yanxia Zhu T, Liu KS, et al. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008;26:664–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Gimble JM. Adipose tissue-derived therapeutics. Expert Opin Biol Ther. 2003;3:705–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Bai X, Yan Y, Song YH, et al. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur Heart J. 2010;31:489–501.PubMedCrossRefGoogle Scholar
  23. 23.
    Carey VJ, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol. 1997;145:614–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Bolinder J, Kager L, Ostman J, et al. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 1983;32:117–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Ostman J, Arner P, Engfeldt P, Kager L. Regional differences in the control of lipolysis in human adipose tissue. Metabolism. 1979;28:1198–205.PubMedCrossRefGoogle Scholar
  26. 26.
    Richelsen B, Pedersen SB, Moller-Pedersen T, et al. Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism. 1991;40:990–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555–63.PubMedGoogle Scholar
  28. 28.
    Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. Circulation. 2007;116:1234–41.PubMedCrossRefGoogle Scholar
  29. 29.
    von Eyben FE, Mouritsen E, Holm J, et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults[ast]. Int J Obes Relat Metab Disord. 2003;27:941–9.CrossRefGoogle Scholar
  30. 30.
    Baglioni S, Francalanci M, Squecco R, et al. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J. 2009;23:3494–505.PubMedCrossRefGoogle Scholar
  31. 31.
    Tholpady SS, Katz AJ, Ogle RC. Mesenchymal stem cells from rat visceral fat exhibit multipotential differentiation in vitro. Anat Rec A Discov Mol Cell Evol Biol. 2003;272A:398–402.CrossRefGoogle Scholar
  32. 32.
    Singh A, Patel J, Litbarg N, et al. Stromal cells cultured from omentum express pluripotent markers, produce high amounts of VEGF, and engraft to injured sites. Cell Tissue Res. 2008;332:81–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Toyoda M, Matsubara Y, Lin K, et al. Characterization and comparison of adipose tissue-derived cells from human subcutaneous and omental adipose tissues. Cell Biochem Funct. 2009;27:440–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Mohammadi R, Azizi S, Delirezh N, et al. Comparison of beneficial effects of undifferentiated cultured bone marrow stromal cells and omental adipose-derived nucleated cell fractions on sciatic nerve regeneration. Muscle Nerve. 2011;43:157–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Dhanasekaran M, Indumathi S, Kanmani, A et al. (2012) Surface Antigenic Profiling Of Stem Cells from Human Omentum Fat In Comparison with Subcutaneous Fat and Bone Marrow. Cytotechnology. 64(5):497–509.PubMedCentralCrossRefGoogle Scholar
  36. 36.
    Fujioka S, Tokunaga K, Kawamoto T, et al. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes. 1991;15:853–9.PubMedGoogle Scholar
  37. 37.
    Feinleib M. Epidemiology of obesity in relation to health hazards. Ann Intern Med. 1985;103:1019–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham study. Am Heart J. 1985;110:1100–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Keys A. Overweight, obesity, coronary heart disease and mortality. Nutr Rev. 1980;38:297–307.PubMedCrossRefGoogle Scholar
  40. 40.
    Mann GV. The influence of obesity and health: part 2. N Engl J Med. 1974;291:226–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obes. 1991;15:53–7.PubMedGoogle Scholar
  42. 42.
    Vague J. La differe´nciation sexuelle, facteur determinant des formes de l’obe´site´. Presse me´d. 1947;55:339–40.Google Scholar
  43. 43.
    Alvarez-Llamas G, Szalowska E, Marcel de Vries P. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics. 2007;6(4):589–600.PubMedCrossRefGoogle Scholar
  44. 44.
    Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes. 2008;32:S13–8. doi: 10.1038/ijo.2008.233.CrossRefGoogle Scholar
  45. 45.
    Arita Y, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.PubMedCrossRefGoogle Scholar
  46. 46.
    Ryo M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Yatagai T, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 2003;52:1274–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Yamamoto Y, Hirose H, Saito I, et al. Adiponectin, an adipocyte-derived protein, predicts future insulin-resistance: 2-year follow-up study in Japanese population. J Clin Endocrinol Metab. 2004;89:87–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Herrera MF, Pantoja JP, David V-F, et al. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass. Diabetes Care. 2010;33:1413–8.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    DiMascio L, Voermans C, Uqoezwa M, et al. Identification of adiponectin as a novel hematopoietic stem cell growth factor. J Immunol. 2007;178:3511–20.PubMedCrossRefGoogle Scholar
  51. 51.
    Yuchang F, Nanlan L, Klein RL, et al. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res. 2005;46:1369–79.CrossRefGoogle Scholar
  52. 52.
    Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35:842–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Blouin K, Richard C, Belanger C, et al. Local androgen inactivation in abdominal visceral adipose tissue. J Clin Endocrinol Metab. 2003;88(12):5944–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Pinho Mde F, Hurtado SP, El Cheikh MC, et al. Myelopoiesis in the omentum of normal mice and during abdominal inflammatory processes. Cell Tissue Res. 2002;308:87–96.PubMedCrossRefGoogle Scholar
  55. 55.
    Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-B signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–301.PubMedCrossRefGoogle Scholar
  56. 56.
    Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–63.PubMedCrossRefGoogle Scholar
  57. 57.
    Lafontan M, Girard J. Impact of visceral adipose tissue on liver metabolism Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. 2008;34:317–27.PubMedCrossRefGoogle Scholar
  58. 58.
    Potdar PD, Jyoti PS. Establishment and molecular characterization of mesenchymal stem cell lines derived from human visceral & subcutaneous adipose tissues. J Stem Cells Regen Med. 2010;6:26–35.PubMedCentralPubMedGoogle Scholar
  59. 59.
    van Harmelen V, Rohrig K, Hauner H. Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects. Metabolism. 2004;53:632–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Dhanasekaran M, Indumathi S, Rajkumar JS, et al. (2012) Long term culture optimization of human omentum fat derived mesenchymal stem cells. Cell Biol Int Doi: 10.1042/CBI20120201.
  61. 61.
    Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33:1402–16.PubMedCrossRefGoogle Scholar
  63. 63.
    McIntosh K, Zvonic S, Garrett S, et al. The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells. 2006;24:1246–53.PubMedCrossRefGoogle Scholar
  64. 64.
    Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005;129:118–29.PubMedCrossRefGoogle Scholar
  65. 65.
    Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–95.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–28.PubMedCrossRefGoogle Scholar
  68. 68.
    Tchkonia T, Tchoukalova YD, Giorgadze N, et al. Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab. 2005;288:E267–77.PubMedCrossRefGoogle Scholar
  69. 69.
    Kingham PJ, Kalbermatten DF, Mahay D, et al. Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Exp Neurol. 2007;207:267–74.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Somasundaram Indumathi
    • 1
    • 2
  • Radhakrishnan Harikrishnan
    • 3
    • 2
  • Marappagounder Dhanasekaran
    • 4
    • 2
  1. 1.Department of Stem CellsNational Institute of NutritionTarnaka, SecunderabadIndia
  2. 2.Lifeline RIGID HospitalsKilpauk, ChennaiIndia
  3. 3.Translational Oncology of Solid Tumours, Berlin School of Integrative OncologyCharité – Universitätsmedizin Berlin, AG Stein, Max-Delbrück-Centrum für Molekulare Medizin (MDC)BerlinGermany
  4. 4.Stemcell Banking and TherapeuticsRee Laboratories Private LimitedAndheri West, MumbaiIndia

Personalised recommendations